Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (5.556%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hygea VCT Net Asset Value Drops In Half-Year As Scancell Shares Slide

Wed, 31st Aug 2016 11:37

LONDON (Alliance News) - Medical technology investment fund Hygea VCT PLC reported a total negative return for the first half of the year and said it was largely due to a drop in the shares of Scancell Holdings PLC, an AIM-listed company focused on cancer treatment.

Hygea said its net asset value per share was down to 69.1 pence a share at June 30 from 75.5p at the end of 2015. The venture capital trust declared no interim dividend, saying the current state of the AIM market "is not conducive to significant realisations".

Hygea shares were untraded at 45.00p Wednesday.

Hygea said the fall was driven by a negative capital return of 5.7p, as its AIM portfolio lost value, principally due to Scancell shares dropping to 16.25p a share from 21.5p a share in the half year. It noted that the value of its AIM portfolio dropped to less than half of the company's total assets. Scancell was untraded at 18.00p Wednesday, down 17% so far in 2016.

Hygea has investments in four AIM-quoted companies and 11 unquoted companies. The investment company said it made no changes to its unquoted portfolio apart from a further GBP200,000 investment in pesticide technology company Exosect.

"At our AGM in June, which was attended by a number of shareholders, the majority view remains that the portfolio holds significant potential, and we should minimise the sale of our portfolio holdings at the present time. Your board agrees and remains optimistic of the outcome for the fund notwithstanding the continuing delays in the timetable for any realisations" said Hygea Chairman John Hustler.

By Adam Clark; adamclark@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
22 Oct 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 Oct 2021 20:41

IN BRIEF: Scancell bases new facility at Oxford Science Park

IN BRIEF: Scancell bases new facility at Oxford Science Park

Read more
5 Oct 2021 22:03

IN BRIEF: Scancell doses first subject in Covidity phase one trial

IN BRIEF: Scancell doses first subject in Covidity phase one trial

Read more
26 Aug 2021 12:53

TRADING UPDATES: Caerus, Bezant pick Cyprus asset; TomCo buys JV

TRADING UPDATES: Caerus, Bezant pick Cyprus asset; TomCo buys JV

Read more
26 Aug 2021 12:38

Scancell gets MHRA approval for Modi-1 clinical trial

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that the UK Medicines and Healthcare products Regulatory Authority (MHRA) has approved the clinical trial application to initiate the first-in-human phase 1 and 2 clinical study of 'Modi-1'.

Read more
17 Aug 2021 15:32

Scancell chooses needle-free tech for Covid vaccine candidates

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell has selected the PharmaJet needle-free injection system to administer its two SARS-CoV-2 vaccine candidates for Covid-19, 'SCOV1' and 'SCOV2', in its 'COVIDITY' phase 1 clinical trial, it announced on Tuesday.

Read more
30 Jul 2021 14:24

DIRECTOR DEALINGS: Harbour Energy CEO for Europe buys 100,000 shares

DIRECTOR DEALINGS: Harbour Energy CEO for Europe buys 100,000 shares

Read more
29 Jul 2021 22:08

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

Read more
28 Jul 2021 22:00

IN BRIEF: Scancell turns once again to Durrant to lead company

IN BRIEF: Scancell turns once again to Durrant to lead company

Read more
22 Jun 2021 15:21

Scancell makes progress with 'Covidity' trial plans

(Sharecast News) - Immunotherapy developer Scancell updated the market on 'Covidity' clinical trial plans, and the publication of preclinical data on two vaccine candidates from the research programme.

Read more
22 Jun 2021 12:14

IN BRIEF: Scancell plans new Covid vaccine trial in South Africa, UK

IN BRIEF: Scancell plans new Covid vaccine trial in South Africa, UK

Read more
7 Jun 2021 13:58

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys more shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys more shares

Read more
7 Jun 2021 10:38

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

Read more
30 Apr 2021 14:30

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

Read more
19 Feb 2021 20:13

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.